What tests should I get after a Triple-Negative Breast Cancer diagnosis

Testing After a Triple-Negative Breast Cancer Diagnosis

I'm glad you're thinking about what tests you need—having the right information helps you work effectively with your care team. Let me walk you through the standard testing approach for triple-negative breast cancer (TNBC).

Initial Diagnostic Testing

According to NCCN Guidelines for Invasive Breast Cancer, after your TNBC diagnosis, your care team should perform several key tests:

Core Tumor Characterization Tests

Your pathology report should confirm:

• ER/PR status (Estrogen and Progesterone Receptors) — which will be negative in TNBC
• HER2 status (Human Epidermal Growth Factor Receptor 2) — also negative in TNBC
• Tumor grade — how aggressive the cancer cells appear under the microscope

These three negative results define triple-negative breast cancer and guide treatment decisions.

Genetic Testing (Important for TNBC)

The NCCN Guidelines specifically recommend genetic counseling and testing if you have triple-negative breast cancer. This is important because:

• TNBC has a higher association with BRCA1 and BRCA2 mutations (inherited genetic changes)
• If you carry a BRCA mutation, this opens up specific treatment options like PARP inhibitors (drugs that target this genetic vulnerability)
• Your family members may also benefit from knowing about inherited mutations

Questions to ask your doctor:

1. Should I have genetic testing, and if so, what type?
2. Will this be germline testing (checking your inherited genes) or somatic testing (checking just the tumor)?
3. If I have a BRCA mutation, how does this change my treatment options?

Biomarker Testing for Treatment Planning

Beyond the basic ER/PR/HER2 testing, the NCCN Guidelines recommend comprehensive biomarker testing for TNBC patients. This may include:

• Tumor mutation testing — checking for specific DNA mutations in your cancer cells that might respond to targeted therapies
• PD-L1 testing — an immune protein that helps determine if immunotherapy might work for you
• Tumor mutational burden (TMB) — the number of mutations in your cancer, which can predict immunotherapy response
• Circulating tumor DNA (ctDNA) testing — a "liquid biopsy" using a blood sample to detect cancer DNA

These tests help identify which treatments your specific cancer is most likely to respond to.

Staging and Spread Assessment

To understand if your cancer has spread, you'll need:

• Complete blood count (CBC) and comprehensive metabolic panel — baseline blood work
• Imaging tests based on your situation:
  • Chest CT (to check lungs)
  • Abdominal/pelvic imaging (CT or MRI)
  • Brain MRI (if you have symptoms suggesting spread to the brain)
  • Bone imaging (if bone pain or other concerning symptoms)

Additional Important Assessments

• Pregnancy test (if you're of childbearing age) — important before starting treatment
• Fertility discussion — treatments can affect your ability to have children; discuss options like egg/sperm banking if this matters to you
• Distress screening — assessing your emotional and mental health needs

Questions to Ask Your Oncology Team

1. Which biomarker tests are you recommending for me, and why?
2. Will I have genetic testing? What will it tell us?
3. What imaging tests do I need, and how soon?
4. How will these test results guide my treatment decisions?
5. When will I get results, and who will explain them to me?
6. Can I get copies of all my pathology reports and test results?
7. Are there any clinical trials I might be eligible for based on my biomarkers?

Why This Matters for TNBC

Triple-negative breast cancer doesn't respond to hormone therapy or HER2-targeted drugs, so identifying other treatment targets through comprehensive testing is especially important. The good news is that newer immunotherapy options and targeted therapies have expanded treatment possibilities for TNBC patients in recent years.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.